Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here Today......the other day you said the short position was less. What led you to that conclusion because I see no change on the TD Ameritrade board?
Powerwalker.....I just know from experience when shorts come in they like to raise credibility issues about the stock that is being bashed. There are not many people who come on this board and sorry that I dissed you. I think Here made a very good point and Culpher is always trying to knock down stocks. I am sure the FDA had all the same materials as culpher did when they made their decision based on efficacy.
Also I think the New England Journal did as well. This is really not the home run for the stock. There are other things in the VERU pipeline.
I wouldn't mind seeing this stock run a little bit though.
Culpher tried to short Veru in May saying that their report was BS; however, the FDA stopped the trial due to Veru's drug being safe and then a report from the New England Journal substantiated everything VERU had said. I agree wiith Here Today that this is a hit piece that changes nothing. Most likely (I have not read it), but it probably says the same crap as the last report said. The stock has been holding nicely . As Here Today says why would the New England Journal ratify the FDA findings if it was not true? Also why did Jeffries say that new price target was raised to $55 ; moreover, they said EAU approval within the month. Nothing has changed.
Now Culpher comes out with another hit piece. I think they are scrambling and just trying to take down a legitimate company for the reasons mentioned by Here Today. Funny that all of a sudden you are new to the board and act is if you do not know what is happening. This same stunt was pulled 3 months ago and I have to believe it is substantially the same report.
Hey HereToday,
Veru received a buy from Jeffries with a $55 target and they said that EAU approval can occur within next 30 days. I am wondering how reliable Jeffries is.
Thanks for the information. A friend of mine who is a broker at Morgan Stanley said that this drug was found as a result of the cancer drug, which is their big drug. I think this is the beginning of something big.
Thanks for the information. A friend of mine who is a broker at Morgan Stanley said that this drug was found as a result of the cancer drug, which is their big drug. I think this is the beginning of something big.
The way it is surging after hours I am guessing that the announcement can come tomorrow. But I hear that their big drug is the cancer drug.
The way it is surging after hours I am guessing that the announcement can come tomorrow. But I hear that their big drug is the cancer drug.
Here Today
Hope you are right. I searched your posts and found the IPIX interesting. Tell me a little about that one.
Stark,
They are supposed to announce if they got EAU approval this quarter
thank you
Since I do not have private reply how confident are you that they will get that in your opinion.
Are you concerned about the short interest?
Alleyba says...........
Here today.....I do not know who Mark Berry is, but if you have TD you will see that a whale came in and bought a lot of puts. Do not know if it means anything because he may have hedged long/
Alleyba says.............
Your not squeezing their balls hard enough. I want the shorts to feel the pain.
Alleyba says to tomj 1...............
Clearly how can you say this is a pump and dump when the FDA looked at the efficacy and agreed with the findings. I hate to say this but how can you possibly in that little mind of yours see this as a pump and dump. You obviously did not listen to the earnings report. They clearly debunked the short report and it did not affect the FDA's decision to grant them the right to continue to use the drug. I think this is just a bonus and the other drugs that are in phase 3 clinical trials are the ones they are hoping for. I would not be surprised if someone comes along and offers a massive buyout.
I am hoping that they continue to squeeze your short balls and close it much higher next week. NO SIDE EFFECTS. This is better than PFIZER and MDNA. They wanted to let you see the side effects in 75 years and no side effects were found with this drug.
Alleyba says.............
squeeze their balls harder until they scream in pain
Alleyba says:
Squeeze those shorts so they feel pain. Keep buying. The phony report was debunked in the earnings call. I hope they are running like the cockroaches that they are.
Xurefox,
Whatever was done was in the past. Apparently the FDA has no problem with the efficacy of their findings. This is a new company with solid products.
ALLEYBA SAYS........
It looked like Culper picked the wrong stock to short. Apparently he never read the FDA report, or part of the report where they said the efficacy was fine and they halted the experiment of the study because they found the drug to be safe. I think, in my opinion, that the company should look into bringing a class action on behalf of all shareholders for stopping the rise of this stock dead in it's tracks. I am sure they, in my opinion hedged themselves long when they decided to short the stock. Does anyone here share my opinion?
Alleyba says:
and they further remarked that no safety concerns were identified.
This is what the FDA said about Veru's application. So if there were no safety concerns I have to imagine then there was nothing wrong with the study and the report is a piece of crap. I am sure they hedged with higher calls
Alleyba says:
Veru Inc. (NASDAQ: VERU) CEO Mitchell Steiner, M.D: "Sabizabulin Delivers Significant Milestone in COVID-19"
Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company, today announced positive efficacy and safety results from a planned interim analysis of the double-blind, randomized, placebo-controlled Phase 3 COVID-19 clinical trial evaluating oral sabizabulin 9 mg versus placebo in 150 hospitalized COVID-19 patients at high risk for Acute Respiratory Distress Syndrome (ARDS). The Independent Data Safety Monitoring Committee unanimously recommended that the Phase 3 study be halted early due to efficacy, and they further remarked that no safety concerns were identified.
CEO Mitchell Steiner, M.D, commented: "This study represents a significant milestone in the global fight against COVID-19 as sabizabulin is the first drug to demonstrate a clinically and statistically meaningful reduction in deaths in hospitalized patients with moderate to severe COVID-19. We strongly believe that sabizabulin, with its dual anti-viral and anti-inflammatory properties which demonstrated positive efficacy and safety results in the Phase 3 COVID-19 study, can be that greatly needed oral therapy for hospitalized moderate to severe COVID-19 patients."
Veru Inc. (NASDAQ: VERU) News: https://www.wallstreetreporter.com/2022/04/11/verus-novel-covid-19-drug-candidate-reduces-deaths-by-55/
Alleyba says:
Veru Inc. (NASDAQ: VERU) CEO Mitchell Steiner, M.D: "Sabizabulin Delivers Significant Milestone in COVID-19"
Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company, today announced positive efficacy and safety results from a planned interim analysis of the double-blind, randomized, placebo-controlled Phase 3 COVID-19 clinical trial evaluating oral sabizabulin 9 mg versus placebo in 150 hospitalized COVID-19 patients at high risk for Acute Respiratory Distress Syndrome (ARDS). The Independent Data Safety Monitoring Committee unanimously recommended that the Phase 3 study be halted early due to efficacy, and they further remarked that no safety concerns were identified.
CEO Mitchell Steiner, M.D, commented: "This study represents a significant milestone in the global fight against COVID-19 as sabizabulin is the first drug to demonstrate a clinically and statistically meaningful reduction in deaths in hospitalized patients with moderate to severe COVID-19. We strongly believe that sabizabulin, with its dual anti-viral and anti-inflammatory properties which demonstrated positive efficacy and safety results in the Phase 3 COVID-19 study, can be that greatly needed oral therapy for hospitalized moderate to severe COVID-19 patients."
Veru Inc. (NASDAQ: VERU) News: https://www.wallstreetreporter.com/2022/04/11/verus-novel-covid-19-drug-candidate-reduces-deaths-by-55/
Alleyba says..........that he hears the stock IS restricted and cannot be sold for 8 months.
Hi. I am new to the board. Can you tell me whether or not you think this company will be successful and is there anything else you can tell me about this xompany
Alleyba says................that he heard after hours yesterday that IHAI reduced the number of their OS by 50%. That means that 1/2 the number of shares are OS. Can this be the prelude to something big?
43 shares at end of day looks like a paint job to me
Thanks for the link. Do you know or have a link that the deal actually closed
please send link to the $50 million dollar contract
Where did the stock close at on Friday
Do you have the name and telephone number of a Canadian market maker as i want to buy more of LRDG
if suspension lifted is stock then put back on board, not grey sheets? E-trade and TD trade on that exchange FYI
i have a question off of this article:
Some of the companies affected have been the targets of short-selling reports alleging fraudulent claims relating to the virus, that address misdeeds conducted by executives at other companies.
Predictive Technology Group Inc. and SCWorx Corp., for example, have both been the subjects of reports by Hindenburg Research (https://hindenburgresearch.com/)that alleged that certain executives had been embroiled in securities fraud suits in the past. Nathan Anderson, partner at Hindenburg, commended the SEC on Wednesday for its action.
Does the SEC realize Hindenburg is selling stock short and isn't that a conflict of interest for Hindenburg to be able to deal directly with SEC in my opinion. if hindenburg knew what SEC was going to do is that inside information or not? when did Hindenbrg learn SEC was taking these steps? Just questions in my mind. Not making allegations, but no one has raised these questions
Why doesn't the company refute the allegations? I thought that was a mistake the last time with Hidenberg and look what happened to the stock and now they are silent once again. Explain that to me
then why aren't kits being delivered and sold? And if they are why doesn't company come out and sayit?
I believe Martin, but you still need the approval of the EAU
See my last post Gumby. Are you anticipating that all sales will be outside U.S.
I agree with Martin.....but the question I raised weeks ago is will they be able to market the kits in this country. They need EAU approval. This paragraph from an article ii read concerned me a little:
Predictive is also pursuing procurement authorization through the Biomedical Advance Research and Development Authority (BARDA) under the Office of the Assistant Secretary for Preparedness and Response (ASPR) in Health and Human Services (HHS). The Company cautions that if the federal government decides to restrict adequate reimbursement or the foreign import of products manufactured in Asia, the Company will not be able to provide access to these tests in the U.S.
The last sentence bothered me. What is the hold up in EAU approval. The kit looks terrific as a diagnostic tool. Should i be concerned?
Gumby,
how do you know the number of kits PRED has sold?
Take a look at MTDR and tell me what you think. Check out the insider trading (buying) and the analysts targets